Article
Clinical Neurology
Eric E. Abrahamson, Julia K. Kofler, Carl R. Becker, Julie C. Price, Kathy L. Newell, Bernardino Ghetti, Jill R. Murrell, Catriona A. McLean, Oscar L. Lopez, Chester A. Mathis, William E. Klunk, Victor L. Villemagne, Milos D. Ikonomovic
Summary: In a post-mortem study, it has been found that the amyloid PET radioligand Pittsburgh compound B (PiB) interacts poorly with cotton wool plaques, which are common in familial Alzheimer's disease but rare in sporadic Alzheimer's disease. This limited interaction may lead to an underestimation of total amyloid burden in patients with familial Alzheimer's disease.
Article
Radiology, Nuclear Medicine & Medical Imaging
Vincent Dore, Natasha Krishnadas, Pierrick Bourgeat, Kun Huang, Shenpeng Li, Samantha Burnham, Colin L. Masters, Jurgen Fripp, Victor L. Villemagne, Christopher C. Rowe
Summary: The study found that Aβ levels between 10 and 40 CL are associated with spreading of tau protein in different brain regions, and abnormal levels of tau protein in the neocortex require Aβ levels above 40 CL. The highest prevalence of abnormal tau protein was found in the entorhinal cortex.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Pharmacology & Pharmacy
Ilker Ozsahin, Efe Precious Onakpojeruo, Berna Uzun, Dilber Uzun Ozsahin, Tracy A. A. Butler
Summary: The use of positron emission tomography (PET) imaging with tau-specific radiotracers allows for the detection and quantification of tau pathology in living subjects, which aids in the early diagnosis of Alzheimer's disease (AD) and monitoring disease progression and treatment effectiveness. This study analyzed, compared, and ranked currently available tau PET radiotracers using a multi-criteria decision-making (MCDM) tool called PROMETHEE. Based on weighted criteria such as specificity, target binding affinity, brain uptake, brain penetration, and rates of adverse reactions, the second-generation tau tracer [F-18]RO-948 was found to be the most favorable. This flexible method can be expanded and updated to assist researchers and clinicians in choosing the optimal tau PET tracer for specific purposes.
Article
Neurosciences
Lilia Jorge, Ricardo Martins, Nadia Canario, Carolina Xavier, Antero Abrunhosa, Isabel Santana, Miguel Castelo-Branco
Summary: The study found significant differences in levels of atrophy, neuroinflammation, and A beta deposition between AD patients and healthy controls. Associations between A beta aggregation and brain atrophy were more prominent than those between neuroinflammation and cortical atrophy, indicating a significant role of A beta in neurodegeneration at an early stage of AD.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Neurosciences
Xi Chen, Kaitlin E. Cassady, Jenna N. Adams, Theresa M. Harrison, Suzanne L. Baker, William J. Jagust
Summary: Studies suggest that tau deposition begins in the anterolateral entorhinal cortex during normal aging and is facilitated by the presence of beta-amyloid, potentially marking the onset of Alzheimer's disease. Higher tau deposition in the anterior-temporal memory network is associated with faster memory decline, especially in individuals with beta-amyloid. When all three tau measures are considered, only tau in the anterior-temporal region significantly predicts memory decline.
JOURNAL OF NEUROSCIENCE
(2021)
Article
Clinical Neurology
Wha Jin Lee, Hanna Cho, Min Seok Baek, Han-Kyeol Kim, Jae Hoon Lee, Young Hoon Ryu, Chul Hyoung Lyoo, Joon-Kyung Seong
Summary: This study describes the differences in tau-spreading processes in early- and late-onset Alzheimer's disease spectrum. The results suggest that the tau propagation pathways are distinct between individuals with early and late onset of symptoms, with specific hub regions playing a dominant role in tau spreading.
ALZHEIMERS RESEARCH & THERAPY
(2022)
Article
Medicine, General & Internal
Nicholas J. Ashton, Andrea L. Benedet, Tharick A. Pascoal, Thomas K. Karikari, Juan Lantero-Rodriguez, Wagner S. Brum, Sulantha Mathotaarachchi, Joseph Therriault, Melissa Savard, Mira Chamoun, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Serge Gauthier, Eduardo R. Zimmer, Henrik Zetterberg, Kaj Blennow, Pedro Rosa-Neto
Summary: CSF p-tau epitopes increase early in the development of AD pathology and are a primary candidate for detecting incipient Aβ pathology.
Article
Clinical Neurology
Hana Florian, Deli Wang, Steven E. Arnold, Merce Boada, Qi Guo, Ziyi Jin, Hui Zheng, Nahome Fisseha, Hari Varun Kalluri, Beatrice Rendenbach-Mueller, Kumar Budur, Michael Gold, Thomas Aware Investigators, Lealani Acosta, Thomas Ala, Sanka Amadoru, Jeffrey Apter, Steven Arnold, Merce Boada-Rovira, Anne Boerjesson-Hanson, Wendy Bond, Michael Borrie, Gabriella Bottini, Bruce Brew, Mark Brody, James Burke, Jeffrey Burns, Annalisa Chiari, Roger Clarnette, Sharon Cohen, Martin Farlow, Simon Fishman, Norman Foster, Kristian Frederiksen, Giovanni Frisoni, Nigel Gilchrist, Darren Gitelman, Ira Goodman, Marc Gordon, Neill Graff-Radford, Merja Hallikainen, Adrian Ivanoiu, Gregory Jicha, Michael Jonsson, Diana Kerwin, Dineke Koek, James Lah, Ayesha Lall, Elly Lee, Gabriel Leger, Peter Ljubenkov, Camillo Marra, Pablo Martinez-Lage, Joseph Masdeu, Scott McGinnis, Patrizia Mecocci, Philip Morris, Marshall Nash, Allison Perrin, Aimee Pierce, Robert Riesenberg, Juha Rinne, Raquel Sanchez Del Valle, Elio Scarpini, Paul Schulz, Ronald Schwartz, Amanda Smith, Bryan Spann, Sylvie Van Snick, Rik Vandenberghe, Cherian Verghese, Alberto Villarejo, Chuang-Kuo Wu
Summary: Tau accumulation in patients with Alzheimer's disease is closely related to cognitive decline. This study evaluated tilavonemab, an anti-tau monoclonal antibody, in treating patients with early Alzheimer's disease. The results showed that tilavonemab did not demonstrate efficacy in treating early Alzheimer's disease.
Article
Clinical Neurology
Gregory Klein, P. Delmar, G. A. Kerchner, C. Hofmann, D. Abi-Saab, A. Davis, N. Voyle, M. Baudler, P. Fontoura, R. Doody
Summary: The study demonstrates that prolonged treatment with high-dose gantenerumab can reduce amyloid plaque levels below the positivity threshold in patients with early to moderate Alzheimer's disease, showing continued reduction in amyloid plaque removal over time. Ongoing Phase III trials will evaluate the potential clinical benefits of gantenerumab-induced amyloid lowering in early-stage Alzheimer's disease patients.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2021)
Review
Neurosciences
Baosheng Chen, Bernadette Marquez-Nostra, Erika Belitzky, Takuya Toyonaga, Jie Tong, Yiyun Huang, Zhengxin Cai
Summary: This study reviews the current state of preclinical PET imaging using animal models of Alzheimer's disease (AD), highlighting its importance in understanding AD pathogenesis/progression and the development of novel treatments. Future research directions are also suggested.
FRONTIERS IN NEUROSCIENCE
(2022)
Article
Clinical Neurology
Olin Janssen, Willemijn J. Jansen, Stephanie J. B. Vos, Merce Boada, Lucilla Parnetti, Tomasz Gabryelewicz, Tormod Fladby, Jose Luis Molinuevo, Sylvia Villeneuve, Jakub Hort, Stephane Epelbaum, Alberto Lleo, Sebastiaan Engelborghs, Wiesje M. van der Flier, Susan Landau, Julius Popp, Anders Wallin, Philip Scheltens, Marcel Olde Rikkert, Peter J. Snyder, Chris Rowe, Gael Chetelat, Agustin Ruiz, Marta Marquie, Elena Chipi, Steffen Wolfsgruber, Michael Heneka, Henning Boecker, Oliver Peters, Jonas Jarholm, Lorena Rami, Adria Tort-Merino, Alexa Pichet Binette, Judes Poirier, Pedro Rosa-Neto, Jiri Cerman, Bruno Dubois, Marc Teichmann, Daniel Alcolea, Juan Fortea, M. Belen Sanchez-Saudinos, Jarith Ebenau, Cornelia Pocnet, Marie Eckerstrom, Louisa Thompson, Victor Villemagne, Rachel Buckley, Samantha Burnham, Marion Delarue, Yvonne Freund-Levi, Asa K. Wallin, Inez Ramakers, Magda Tsolaki, Hilkka Soininen, Harald Hampel, Luiza Spiru, Betty Tijms, Rik Ossenkoppele, Frans R. J. Verhey, Frank Jessen, Pieter Jelle Visser
Summary: In addition to age, setting, and APOE ε4 carriership, specific characteristics of subjective cognitive decline may aid in identifying individuals with amyloid positivity.
ALZHEIMERS & DEMENTIA
(2022)
Article
Clinical Neurology
Stephen Zicha, Randall J. Bateman, Leslie M. Shaw, Henrik Zetterberg, Anthony W. Bannon, Wesley A. Horton, Mike Baratta, Hartmuth C. Kolb, Iwona Dobler, Yulia Mordashova, Ziad S. Saad, David L. Raunig, Emmanouil (Manos) Spanakis, Yan Li, Suzanne E. Schindler, Kyle Ferber, Carrie E. Rubel, Robert L. Martone, Christopher J. Weber, Rebecca M. Edelmayer, Emily A. Meyers, James G. Bollinger, Erin G. Rosenbaugh, William Z. Potter
Summary: This study evaluated the performance of six plasma A beta assays in predicting amyloid positivity compared to age and APOE genotype. The results showed that three of the assays significantly improved the prediction accuracy, and plasma A beta 42/40 predicted amyloid PET status better than A beta 42 or A beta 40 alone.
ALZHEIMERS & DEMENTIA
(2023)
Article
Neurosciences
Se Jong Oh, Namhun Lee, Kyung Rok Nam, Kyung Jun Kang, Sang Jin Han, Kyo Chul Lee, Yong Jin Lee, Jae Yong Choi
Summary: This study aimed to investigate the impact of amyloid pathology on the functional aspects of neurotransmitter systems in Alzheimer's disease. The results revealed increased amyloid pathology in the AD group, as well as decreased glutamatergic and GABAergic systems and a reduction in the dopaminergic system. These findings suggest a connection between dysfunction of neurotransmitter systems and AD pathology.
FRONTIERS IN NEUROSCIENCE
(2022)
Review
Clinical Neurology
Lyduine E. Collij, Gill Farrar, David Vallez Garcia, Ilona Bader, Mahnaz Shekari, Luigi Lorenzini, Hugh Pemberton, Daniele Altomare, Sandra Pla, Mery Loor, Pawel Markiewicz, Maqsood Yaqub, Christopher Buckley, Giovanni B. Frisoni, Agneta Nordberg, Pierre Payoux, Andrew Stephens, Rossella Gismondi, Pieter Jelle Visser, Lisa Ford, Mark Schmidt, Cindy Birck, Jean Georges, Anja Mett, Zuzana Walker, Merce Boada, Alexander Drzezga, Rik Vandenberghe, Bernard Hanseeuw, Frank Jessen, Michael Scholl, Craig Ritchie, Isadora Lopes Alves, Juan Domingo Gispert, Frederik Barkhof, AMYPAD Consortium
Summary: Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium aims to provide evidence on the clinical utility and cost-effectiveness of Positron Emission Tomography (PET) imaging in AD diagnosis and support clinical trial design. AMYPAD has contributed significantly to understanding of amyloid deposition in the brain and improving measurement methodology. Future steps include integrating and curating available clinical data for wider scientific access.
FRONTIERS IN NEUROLOGY
(2023)
Article
Medicine, General & Internal
Cecile Tissot, Joseph Therriault, Peter Kunach, Andrea L. Benedet, Tharick A. Pascoal, Nicholas J. Ashton, Thomas K. Karikari, Stijn Servaes, Firoza Z. Lussier, Mira Chamoun, Dana L. Tudorascu, Jenna Stevenson, Nesrine Rahmouni, Nina Margherita Poltronetti, Vanessa Pallen, Gleb Bezgin, Min Su Kang, Sulantha S. Mathotaarachchi, Yi-Ting Wang, Jaime Fernandez Arias, Pamela Cristina Lukasewicz Ferreira, Joao Pedro Ferrari-Souza, Eugeen Vanmechelen, Kaj Blennow, Henrik Zetterberg, Serge Gauthier, Pedro Rosa-Neto
Summary: This study investigated the agreement between [F-18]MK6240 tau-PET, plasma pTau181, and pTau231 in Alzheimer's disease. The findings suggest that these biomarkers reflect different stages of tau progression and can be useful in diagnosing and evaluating the disease stage.
Article
Endocrinology & Metabolism
Min Su Kang, Monica Shin, Julie Ottoy, Arturo Aliaga Aliaga, Sulantha Mathotaarachchi, Kely Quispialaya, Tharick A. Pascoal, D. Louis Collins, M. Mallar Chakravarty, Axel Mathieu, Asa Sandelius, Kaj Blennow, Henrik Zetterberg, Gassan Massarweh, Jean-Paul Soucy, A. Claudio Cuello, Serge Gauthier, Michael Waterston, Nathan Yoganathan, Etienne Lessard, Arsalan Haqqani, Kerry Rennie, Danica Stanimirovic, Balu Chakravarthy, Pedro Rosa-Neto
Summary: This study utilized in vivo longitudinal study design and a variety of biomarkers to evaluate the efficacy of a novel brain-penetrating anti-amyloid fusion protein treatment in a transgenic rat model of Alzheimer's disease. The treatment significantly reduced brain amyloid-beta levels and improved related biomarkers.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
(2022)
Article
Biochemistry & Molecular Biology
Chiara Orciani, Helene Hall, Rowan Pentz, Morgan K. Foret, Sonia Do Carmo, Augusto Claudio Cuello
Summary: The destruction of cholinergic nuclei in the basal forebrain can impair cognition and reduce cortical neuron markers, while also affecting brain-derived neurotrophic factor (BDNF) levels, but not nerve growth factor (NGF) levels.
JOURNAL OF NEUROCHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Douglas T. Leffa, Joao Pedro Ferrari-Souza, Bruna Bellaver, Cecile Tissot, Pamela C. L. Ferreira, Wagner S. Brum, Arthur Caye, Jodie Lord, Petroula Proitsi, Thais Martins-Silva, Luciana Tovo-Rodrigues, Dana L. Tudorascu, Victor L. Villemagne, Ann D. Cohen, Oscar L. Lopez, William E. Klunk, Thomas K. Karikari, Pedro Rosa-Neto, Eduardo R. Zimmer, Brooke S. G. Molina, Luis Augusto Rohde, Tharick A. Pascoal
Summary: The genetic liability for attention-deficit/hyperactivity disorder (ADHD) is associated with cognitive decline and the development of Alzheimer's Disease (AD) pathology, especially in individuals with increased amyloid-beta (Aβ) deposition.
MOLECULAR PSYCHIATRY
(2023)
Article
Clinical Neurology
Joseph Therriault, Marie Vermeiren, Stijn Servaes, Cecile Tissot, Nicholas J. Ashton, Andrea Lessa Benedet, Thomas K. Karikari, Juan Lantero-Rodriguez, Wagner S. Brum, Firoza Z. Lussier, Gleb Bezgin, Jenna Stevenson, Nesrine Rahmouni, Peter Kunach, Yi-Ting Wang, Jaime Fernandez-Arias, Kely Quispialaya Socualaya, Arthur C. Macedo, Joao Pedro Ferrari-Souza, Pamela C. L. Ferreira, Bruna Bellaver, Douglas T. Leffa, Eduardo R. Zimmer, Paolo Vitali, Jean-Paul Soucy, Gallen Triana-Baltzer, Hartmuth C. Kolb, Tharick A. Pascoal, Paramita Saha-Chaudhuri, Serge Gauthier, Henrik Zetterberg, Kaj Blennow, Pedro Rosa-Neto
Summary: This study investigates the association between cerebrospinal fluid (CSF) and plasma p-tau biomarkers and the hallmark pathologies of Alzheimer's disease (AD): amyloid-beta plaques and tau neurofibrillary tangles. The results suggest that p-tau is mainly associated with amyloid-beta accumulation, indicating that p-tau abnormalities may be an early event in the pathogenesis of AD.
Article
Neurosciences
Marina Tedeschi Dauar, Tharick Ali Pascoal, Joseph Therriault, Jared Rowley, Sara Mohaddes, Monica Shin, Eduardo R. Zimmer, Simon Fristed Eskildsen, Vladimir S. Fonov, Serge Gauthier, Judes Poirier, Pedro Rosa-Neto
Summary: This study assessed the association between cognitive measures and pathophysiological events in Alzheimer's disease patients, specifically focusing on delayed episodic memory tests. The findings revealed correlations between memory scores and regional amyloid deposition and brain metabolism across different stages of the disease.
Article
Clinical Neurology
Bruna Bellaver, Albert Puig-Pijoan, Joao Pedro Ferrari-Souza, Douglas T. Leffa, Firoza Z. Lussier, Pamela C. L. Ferreira, Cecile Tissot, Guilherme Povala, Joseph Therriault, Andrea L. Benedet, Nicholas J. Ashton, Stijn Servaes, Mira Chamoun, Jenna Stevenson, Nesrine Rahmouni, Marie Vermeiren, Arthur C. Macedo, Aida Fernandez-Lebrero, Greta Garcia-Escobar, Irene Navalpotro-Gomez, Oscar Lopez, Dana L. Tudorascu, Ann Cohen, Victor L. Villemagne, William E. Klunk, Serge Gauthier, Eduardo R. Zimmer, Thomas K. Karikari, Kaj Blennow, Henrik Zetterberg, Marc Suarez-Calvet, Pedro Rosa-Neto, Tharick A. Pascoal
Summary: The permeability of the blood-brain barrier (BBB) may affect the levels of brain-derived proteins in the blood, which in turn can impact the relationship between brain and blood biomarkers. The study found that BBB permeability influenced the relationship between plasma A beta(42/40) and CSF A beta(42/40) as well as A beta-PET positivity, but did not significantly impact the relationship between brain and plasma p-tau levels.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Deming Jiang, Li Liu, Yu Kong, Zhongyun Chen, Pedro Rosa-Neto, Kewei Chen, Liankun Ren, Min Chu, Liyong Wu
Summary: Abnormal glymphatic function, especially in the anterior and middle regions of the brain, was found in patients with bvFTD. Regional glymphatic dysfunction may contribute to the pathogenesis of bvFTD.
ANNALS OF NEUROLOGY
(2023)
Article
Chemistry, Medicinal
Igor C. Fontana, Debora G. Souza, Diogo O. Souza, Antony Gee, Eduardo R. Zimmer, Salvatore Bongarzone
Summary: The excitatory amino acid transporter 2 (EAAT2) is crucial for the clearance and recycling of glutamate, the major excitatory neurotransmitter in the brain. Dysfunctions in EAAT2 can lead to neurodegenerative diseases, such as ALS and AD. Detecting EAAT2 in the living human brain is important for improving diagnosis and therapy for these diseases. This article discusses the role of EAAT2 and presents potential activators for therapy and molecular imaging tools for diagnosis.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Aline Rigon Zimmer, Bianca Franco Leonardi, Eduardo Rigon Zimmer, Alexandre Pastoris Muller, Grace Gosmann, Luis Valmor Cruz Portela
Summary: This study evaluated the protective effects of Capsicum baccatum red pepper on metabolic syndrome induced by an ultra-processed diet in rats. The results showed that oral administration of C. baccatum along with the ultra-processed diet prevented adipose tissue accumulation, reduced total cholesterol and LDL levels, and improved glucose metabolism, all commonly associated with metabolic syndrome. The study suggests that C. baccatum red pepper is a secure and enriched source of bioactive compounds promising to protect against pathological processes associated with metabolic syndrome.
Article
Clinical Neurology
Ricardo A. S. Lima-Filho, Andrea L. Benedet, Marco Antonio De Bastiani, Guilherme Povala, Danielle Cozachenco, Sergio T. Ferreira, Fernanda G. De Felice, Pedro Rosa-Neto, Eduardo R. Zimmer, Mychael Lourenco
Summary: Lima-Filho et al. found that cognitively unimpaired elderly individuals carrying the FNDC5 rs1746661(T) allele exhibited low brain glucose metabolism and increased amyloid deposition. FNDC5 may contribute to regional glucose metabolism in the human brain. This study suggests that FNDC5 is associated with low brain glucose metabolism in elderly individuals and may participate in the regulation of brain metabolism in regions vulnerable to Alzheimer's disease pathophysiology.
BRAIN COMMUNICATIONS
(2023)
Article
Clinical Neurology
Wyllians Vendramini Borelli, Carolina Rodrigues Formoso, Andrei Bieger, Pamela Lukasewicz Ferreira, Eduardo R. Zimmer, Tharick Ali Pascoal, Marcia Lorena Fagundes Chaves, Raphael Machado Castilhos
Summary: Risk factors for dementia vary among different races, and hearing loss is the most important contributor to overall population attributable fraction in all races. Public policies aimed at reducing preventable risk factors for dementia should consider the race of the target populations.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
(2023)
Article
Clinical Neurology
Mychael V. Lourenco, Wyllians Vendramini Borelli, Claudia Duran-Aniotz, Eduardo R. Zimmer, Shamyr Sulyvan de Castro
Summary: Alzheimer's disease (AD) is a global health issue, with immense socioeconomic burden on low- and middle-income countries (LMIC) as well as high-income countries. However, LMICs face disparities in resources and barriers to publishing in international journals, including funding constraints, language barriers, and high article processing charges. The equalization of publication fees by publishing companies could help reduce scientific inequality and improve AD research capacity in LMICs.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
(2023)
Article
Pharmacology & Pharmacy
Pamela C. L. Ferreira, Bruna Bellaver, Guilherme Povala, Wagner S. Brum, Cecile Tissot, Atef Badji, Matthew E. Sloan, Andrea L. Benedet, Pedro Rosa-Neto, Nicholas J. Ashton, Tharick A. Pascoal, Antoine Leuzy, Eduardo R. Zimmer
Summary: Endocannabinoid system biomarkers are associated with the progression and pathological features of Alzheimer's disease. Although not specific enough for diagnosis, they hold promise for prognosis, drug-target engagement, and a better understanding of the disease.
CANNABIS AND CANNABINOID RESEARCH
(2023)
Article
Clinical Neurology
Wyllians Vendramini Borelli, Eduardo R. Zimmer, Andrei Bieger, Bruna Coelho, Tharick A. Pascoal, Marcia Lorena Fagundes Chaves, Rebecca Amariglio, Raphael Machado Castilhos
Summary: This study aimed to estimate the prevalence of subjective cognitive decline (SCD) in Brazil and investigate its association with dementia modifiable risk factors. The results showed a higher prevalence of SCD in Brazil, which was strongly associated with hearing loss, low education, psychological distress, and specific races. Therefore, public strategies targeting SCD may help reduce the incidence of dementia.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
(2022)
Article
Clinical Neurology
Wagner S. Brum, Marco Antonio de Bastiani, Andrei Bieger, Joseph Therriault, Joao P. Ferrari-Souza, Andrea L. Benedet, Paramita Saha-Chaudhuri, Diogo O. Souza, Nicholas J. Ashton, Henrik Zetterberg, Tharick A. Pascoal, Thomas Karikari, Kaj Blennow, Pedro Rosa-Neto, Eduardo R. Zimmer
Summary: This study explores a three-range cut-point method based on cerebrospinal fluid biomarkers for predicting Alzheimer's disease and cognitive decline. The findings demonstrate that this method can better capture the process of cognitive decline and potentially serve as a trial enrichment strategy. This approach has important implications for clinical practice and trial recruitment.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
(2022)
